In paclitaxel-resistant prostate cancer PC3 cells, ETS1 silencing inhibited the activity of the ABCB1 promoter, which contains ETS binding sites, reduced ABCB1 protein, and reversed resistance to paclitaxel[260], an antimicrotubule drug. Here, ABCB1 is linked to Familial prostate cancer.